JP2019521161A - 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用 - Google Patents

肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用 Download PDF

Info

Publication number
JP2019521161A
JP2019521161A JP2019502560A JP2019502560A JP2019521161A JP 2019521161 A JP2019521161 A JP 2019521161A JP 2019502560 A JP2019502560 A JP 2019502560A JP 2019502560 A JP2019502560 A JP 2019502560A JP 2019521161 A JP2019521161 A JP 2019521161A
Authority
JP
Japan
Prior art keywords
weeks
canakinumab
treatment
subject
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019502560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521161A5 (cg-RX-API-DMAC10.html
Inventor
オリバー，ステファン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019521161A publication Critical patent/JP2019521161A/ja
Publication of JP2019521161A5 publication Critical patent/JP2019521161A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019502560A 2016-07-21 2017-07-19 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用 Pending JP2019521161A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365017P 2016-07-21 2016-07-21
US62/365,017 2016-07-21
PCT/IB2017/054360 WO2018015897A1 (en) 2016-07-21 2017-07-19 Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis

Publications (2)

Publication Number Publication Date
JP2019521161A true JP2019521161A (ja) 2019-07-25
JP2019521161A5 JP2019521161A5 (cg-RX-API-DMAC10.html) 2020-08-27

Family

ID=59683618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019502560A Pending JP2019521161A (ja) 2016-07-21 2017-07-19 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用

Country Status (7)

Country Link
US (2) US20210292404A1 (cg-RX-API-DMAC10.html)
EP (1) EP3487584A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019521161A (cg-RX-API-DMAC10.html)
KR (1) KR20190032436A (cg-RX-API-DMAC10.html)
AU (2) AU2017298656A1 (cg-RX-API-DMAC10.html)
CA (1) CA3031346A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018015897A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511540A (ja) * 2008-12-10 2012-05-24 ノバルティス アーゲー 抗体製剤
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511540A (ja) * 2008-12-10 2012-05-24 ノバルティス アーゲー 抗体製剤
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS & RHEUMATISM, vol. 65(2), JPN6021032579, 2013, pages 513 - 518, ISSN: 0004727052 *
CLIN IMMUNOL IMMUNOPATHOL., vol. 51(3), JPN6021032577, 1989, pages 419 - 25, ISSN: 0004727051 *
CURR OPIN CHEM BIOL., vol. 32, JPN6021032581, June 2016 (2016-06-01), pages 1 - 9, ISSN: 0004727053 *
HUM PATHOL., vol. 23, JPN6021032576, 1992, pages 317 - 323, ISSN: 0004727050 *

Also Published As

Publication number Publication date
AU2017298656A1 (en) 2019-02-07
US20220177570A1 (en) 2022-06-09
EP3487584A1 (en) 2019-05-29
WO2018015897A1 (en) 2018-01-25
AU2017298656A2 (en) 2019-03-28
US20210292404A1 (en) 2021-09-23
KR20190032436A (ko) 2019-03-27
CA3031346A1 (en) 2018-01-25
AU2020207771A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
Lukey et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Lim et al. Assessment of coronary flow reserve with transthoracic Doppler echocardiography: comparison among adenosine, standard-dose dipyridamole, and high-dose dipyridamole
Bisi et al. Rest technetium-99m sestmibi temography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories
Barst et al. Four-and seven-year outcomes of patients with congenital heart disease–associated pulmonary arterial hypertension (from the REVEAL Registry)
Yigla et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values
Chen et al. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography
US20110002843A1 (en) Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
Dayton et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies
Santer et al. Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial
Iida et al. Absolute quantitation of myocardial blood flow with 201Tl and dynamic SPECT in canine: optimisation and validation of kinetic modelling
Ohar et al. Diffusing capacity decreases after heart transplantation
Deppen et al. A swine hind limb ischemia model useful for testing peripheral artery disease therapeutics
Washko et al. Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE
Nakanishi 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease
US20220177570A1 (en) Use of the il-1beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis
JP2022518763A (ja) マクロファージ媒介性病理を評価するための組成物および方法
US8809298B2 (en) Methods, compositions, unit dosage forms, and kits testing for pharmacologic stress testing with reduced side effects
Ward et al. Interstitial lung disease: An approach to diagnosis and management
Di Monaco et al. Cardiac adrenergic nerve function in patients with cardiac syndrome X
Abramyuk et al. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors
Nisa et al. The effect of sedation with a combination of butorphanol and midazolam on quantitative contrast-enhanced ultrasonography of duodenum in healthy dogs
Matsushita et al. Use of [123I]-BMIPP myocardial scintigraphy for the clinical evaluation of a fatty-acid metabolism disorder of the right ventricle in chronic respiratory and pulmonary vascular disease
Díaz-Caraballo et al. Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome
Janvier et al. A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results
Hernandez et al. Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315